Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 4/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | PRKACG | P22612 | 1/20 | 0.34 |
| ▸ | PRKACB | P22694 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19715019 | 0.97 | SLC29A1 (0.42) | SLC29A1CDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL17847304 | 0.97 | SLC29A1 (0.43) | SLC29A1CDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL17847266 | 0.95 | SLC29A1 (0.40) | SLC29A1CDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL19714879 | 0.95 | SLC29A1 (0.44) | SLC29A1CDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL19714935 | 0.90 | SLC29A1 (0.46) | SLC29A1CDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL17847272 | 0.90 | SLC29A1 (0.41) | SLC29A1CDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL19714934 | 0.86 | CDK1 (0.39) | SLC29A1CDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL17847682 | 0.86 | SLC29A1 (0.43) | SLC29A1CDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL17847683 | 0.85 | CDK1 (0.38) | SLC29A1CDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL17847273 | 0.83 | CDK1 (0.42) | SLC29A1CDK1CCNB2CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233861-B1 | 6,8-DISUBSTITUTED-9-(HETEROCYCLYL) PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS | USTAV EXPERIMENTALNI BOTANIKY AV CR V V I (CZ) | 2019-04-10 | — | — | EP | disclosed |
| US-10093675-B2 | 6,8-disubstituted-9-(heterocyclyl)purines, compositions containing these derivatives and their use in cosmetic and medicinal applications | USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) | 2018-10-09 | — | — | US | disclosed |
| US-20170362236-A1 | 6,8-DISUBSTITUTED-9-(HETEROCYCLYL)PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS | USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362236-A1 | 6,8-DISUBSTITUTED-9-(HETEROCYCLYL)PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS | PNP, UNG, NUDT1 | SLC29A1 194/4885CDK1 556/4885CCNB2 733/4885 |
| US-10093675-B2 | 6,8-disubstituted-9-(heterocyclyl)purines, compositions containing these derivatives and their use in cosmetic and medicinal applications | PNP, UNG, NUDT1 | SLC29A1 194/4885CDK1 556/4885CCNB2 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.